Amarin Corp Plc (AMRN)

[Laurent Maldague]

skip/bioinvestor i agree. Germany has always been very tough ever since the 2010 AMNOG act, and today's outcome was not a surprise to me. From everything I've read, German negotiators were by statute not allowed to reimburse higher than the "appropriate comparative therapy" which was set to ezetimibe at 45€ a month (this is all because the GBA gave a no benefit added assessment earlier this year).

Arbitration might lead to an acceptable price, but I think the real solution is to re-submit to IQWiG/GBA and get an actual positive benefit assessment.

"For Amarin, which commercializes one single product, it is simply not economically viable to keep Vazkepa on the market in Germany given the outcomes of the G-BA assessment earlier this year, and the subsequent GKV-SV pricing negotiations," said Abuaf.

Following local German legislation which allows re-submission of a pricing and reimbursement dossier with new data, Amarin plans to resubmit once we have a new dossier ready.

I think RESPECT EPA and MITIGATE will be a part of this new submission in my opinion.

https://www.marketscreener.com/quote/stock/AMARIN-CORPORATION-PLC-1658813/news/Amarin-Provides-Update-on-VAZKEPA-icosapent-ethyl-Pricing-Negotiations-in-Germany-Form-8-K-41366521/